Anti-Cytochrome P450 8B1 [M15-P3B7]

Implicated in hepatocellular carcinoma. CYP8B1 is upregulated in primary and metaststic colorectal tumours compared to normal colon mucosa.

Contributors

Inventor Institute
Ayham Alnabulsi Vertebrate Antibodies Limited
Cat. #: 152155
Tool sub type: Primary antibody
Unit size: 100 ug
Research Fields: Cancer;Cell signaling and signal transduction;Metabolism;Tissue-specific biology
Application: ELISA ; IHC ; WB
Target: Cytochrome P450, family 8, subfamily B, polypeptide 1 (CYP8B1)
Reactivity: Human ; Rat
Clone: M15-P3B7
Host: Mouse
Class: Monoclonal
Product description: Implicated in hepatocellular carcinoma. CYP8B1 is upregulated in primary and metaststic colorectal tumours compared to normal colon mucosa.
Conjugation: Unconjugated
Isotype: IgG1 kappa
Immunogen: Peptide sequence QPSHDVRFR (amino acids 486 494)
Myeloma used: P3X63Ag8.653
Target background: Implicated in hepatocellular carcinoma. CYP8B1 is upregulated in primary and metaststic colorectal tumours compared to normal colon mucosa.
Format: Liquid
Concentration: 1 mg/ml
Storage buffer: PBS with 0.02% azide
Storage conditions: -15° C to -25° C
Shipping conditions: Dry ice
References:

Characterisation of the oxysterol metabolising enzyme pathway in mismatch repair proficient and deficient colorectal cancer.

Swan et al. 2016. Oncotarget. :. PMID: 27341022.

Images

View Gallery

Related Tools for Antibodies

Cat. # Tool Name
151015 Anti-CyclinA [E70.1] Key Info View Tool
151024 Anti-Hairy [1/24] Key Info View Tool
151025 Anti-Vascular endothelium [10] Key Info View Tool
151029 Anti-HSVICP8 [11E2] Key Info View Tool
151020 Anti-CyclinB1 [V143.1] Key Info View Tool

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.